Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) kappa (B.1.617.1) variant represented the main variant of concern (VOC) for the epidemic in India in May 2021. We have previously established a technology platform for rapidly preparing SARS-CoV-2 receptor-binding domain (RBD) candidate vaccines based on glycoengineered Pichia pastoris. Our previous study revealed that the wild-type RBD (WT-RBD) formulated with aluminum hydroxide and CpG 2006 adjuvant effectively induces neutralizing antibodies in BALB/c mice. In the present study, a glycoengineered P. pastoris expression system was used to prepare recombinant kappa-RBD candidate vaccine. Kappa-RBD formulated with CpG and alum induced BALB/c mice to produce a potent antigen-specific antibody response and neutralizing antibody titers against pseudoviruses of SARS-CoV-2 kappa, delta, lambda, beta, and omicron variants and WT. Therefore, the recombinant kappa-RBD vaccine has sufficient potency to be a promising COVID-19 vaccine candidate.
Keywords: Receptor-binding domain (RBD); SARS-CoV-2 kappa; Vaccine; Yeast.
【저자키워드】 Vaccine, Receptor-binding domain (RBD), yeast, SARS-CoV-2 kappa, 【초록키워드】 neutralizing antibody, SARS-CoV-2, coronavirus, COVID-19 vaccine, Neutralizing antibodies, VoC, India, variant, severe acute respiratory syndrome Coronavirus, Omicron variants, Receptor-binding domain, RBD, B.1.617.1, Omicron variant, Beta, respiratory, expression, platform, yeast, Antibody titers, Neutralizing antibody titer, CpG, Pichia pastoris, aluminum, alum, pseudoviruses, acute respiratory syndrome, aluminum hydroxide, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, neutralizing antibody titers, domain, hydroxide, candidate vaccine, wild-type, BALB/c mice, antigen-specific antibody, the epidemic, was used, induce, pseudoviruses of SARS-CoV-2, 【제목키워드】 variant, Neutralizing antibody titer, Pichia pastoris, produced, elicited, pseudoviruses of SARS-CoV-2,